source
- FDA schedules September advisory panel to review Grail's cancer test after trial missThe FDA announced it will hold an advisory committee meeting in September to examine Grail's multi‑cancer early detection test. The test recently failed to meet its primary endpoint in a large, ra…
- BlossomHill and Latigo close IPO week with $496 million raisedBlossomHill Therapeutics, a cancer‑focused biotech, completed its initial public offering this week. Latigo, a company developing non‑opioid pain treatments, also went public at the same time. To…